This article is more than 5 years old. Information may no longer be current.

AMO completes purchase of Pfizer’s ophthalmic surgical line

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SANTA ANA, Calif. — Advanced Medical Optics has completed its acquisition of Pfizer’s ophthalmic surgical line, the company announced yesterday. The purchase includes the Healon line of viscoelastic products, the CeeOn and Tecnis IOLs and the Baerveldt glaucoma shunt.

According to a press release from AMO, in 2003 those products generated sales of $150 million. AMO agreed in April to buy the surgical line from Pfizer for $450 million.

The deal also included manufacturing and research and development facilities in the Netherlands, Sweden and India.

AMO has “long respected the superior quality and technological advancements of the Pfizer ophthalmic surgical business,” said James Mazzo, president and chief executive officer of AMO, in the press release. He added that the acquisition of the Baerveldt shunt gives AMO its first entry into the subspecialty of glaucoma.